ITRM - アイテラム・セラピュ―ティクス （Iterum Therapeutics plc） アイテラム・セラピュ―ティクスITRMのチャート
ITRMの企業情報
| symbol | ITRM |
|---|---|
| 会社名 | Iterum Therapeutics plc （アイテラム・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company. The Company is engaged in developing anti-infectives aimed at combatting multi-drug resistant (MDR) pathogens. The Company’s product Sulopenem is a bioavailable antibiotic covering gram-positive gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia (E.) coli and Klebsiella (K.) pneumoniae as well as penicillin-resistant Streptococcus (S.) pneumoniae. アイテラム・セラピュ―ティクスはアイルランドの医薬品持株会社。子会社を通じ、臨床段階で満たされていない医療ニ―ズに対応する治療法の発見・開発に従事する。多くの重症感染症の原因となる多剤耐性病原体を治療する抗感染薬を提供し、複数のバランスのとれた新薬開発に焦点を当てる。本社所在地はダブリン。 |
| 本社所在地 | Block 2 Floor 3 Harcourt Centre Harcourt Street Dublin 2 IRL |
| 代表者氏名 | Paul R. Edick ポールRエディック |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +353 1-903-8920 |
| 設立年月日 | 42156 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 38人 |
| url | www.iterumtx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/itrm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -45.01400 |
| 終値（lastsale） | 6.6 |
| 時価総額（marketcap） | 93452191.8 |
| 時価総額 | 時価総額（百万ドル） 89.62915 |
| 売上高 | 売上高（百万ドル） 0.88400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -32.33185 |
| 当期純利益 | 当期純利益（百万ドル） -45.18200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Iterum Therapeutics PLC revenues increased from $0K to $376K. Net loss increased from $12.1M to $27.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development Expense increase from $4.4M to $12.2M (expense) Research_Development Expense increase from $2.8M to $7.7M (expense). |
ITRMのテクニカル分析
ITRMのニュース
Iterum Therapeutics plc 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:ITRM) 2022/11/10 18:03:26 Seeking Alpha
The following slide deck was published by Iterum Therapeutics plc in conjunction with their 2022 Q3 earnings call.
Iterum Therapeutics plc (ITRM) Q3 2022 Earnings Call Transcript 2022/11/10 16:42:07 Seeking Alpha
Iterum Therapeutics plc (NASDAQ:NASDAQ:ITRM) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Louise Barrett – Senior Vice President-Legal Affairs Corey…
Iterum Therapeutics Plc Tops Q3 EPS by 47c By Investing.com 2022/11/10 12:24:02 Investing.com
Iterum Therapeutics Plc Tops Q3 EPS by 47c
Iterum Therapeutics Non-GAAP EPS of -$0.43 beats by $0.49 2022/11/10 12:01:45 Seeking Alpha
Iterum Therapeutics press release (ITRM): Q3 Non-GAAP EPS of -$0.43 beats by $0.49.Cash, cash equivalents and short-term investments were $64.3 million at September 30, 2022
Iterum Therapeutics Reports Third Quarter 2022 Financial Results 2022/11/10 12:00:00 GlobeNewswire
--Patient Enrollment in Registration Trial for uUTI Underway-- --Cash Runway into 2024--
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem 2022/09/19 11:30:00 GlobeNewswire
DUBLIN, Ireland and CHICAGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the United States Patent and Trademark Office has issued the Company a Notice of Allowance for U.S. patent application number 16/972,300 entitled “Combinations of Beta-Lactam Compounds and Probenecid and Uses Thereof” directed to the composition of the bilayer tablet of sulopenem etzadroxil and probenecid (“oral sulopenem”) and its related uses.
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022/09/07 13:15:00 GlobeNewswire
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Officer, and Judy Matthews, Chief Financial Officer, will provide a company overview and business update at the H.C. Wainwright 24th Annual Hybrid Global Investment Conference at 12:00pm(ET) on Wednesday, September 14, 2022. Management will also host investor meetings on September 13-14, 2022.
Iterum Therapeutics regains Nasdaq compliance as price sclaes above $1 (NASDAQ:ITRM) 2022/09/01 20:33:46 Seeking Alpha
Iterum Therapeutics (ITRM) received a letter from Nasdaq that company has regained compliance with the minimum bid price requirement.Company was previously notified in…
Iterum Therapeutics stock slides on 1-for-15 reverse share split 2022/08/17 09:47:58 Seeking Alpha
Iterum Therapeutics (ITRM) shares dropped 12% pre-market on Wednesday in response to the firm''s 1-for-15 reverse share split announcement.The drugmaker plans to implement the share split…
This stocks will boost Up Your investment: Eargo, Inc. (NASDAQ:EAR 0.88%), Iterum Therapeutics plc (NASDAQ:ITRM 7.65%) 2022/08/16 01:13:32 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post This stocks will boost Up Your investment: Eargo, Inc. (NASDAQ:EAR 0.88%), Iterum Therapeutics plc (NASDAQ:ITRM 7.65%) appeared first on Stocks Equity .
Volume Actives: Iterum Therapeutics plc (NASDAQ:ITRM), The Kroger Co. (NYSE:KR) 2021/12/24 04:31:38 Stock Equity
Iterum Therapeutics plc (NASDAQ:ITRM) with the stream of -0.69% also noticed, India The Kroger Co. (NYSE:KR) encountered a rapid change of -0.71% in the last hour of Thursdays trading session. The post Volume Actives: Iterum Therapeutics plc (NASDAQ:ITRM), The Kroger Co. (NYSE:KR) appeared first on Stocks Equity .
Golden Stock: Iterum Therapeutics plc (NASDAQ:ITRM), United States Antimony Corporation (AMEX:UAMY) 2021/12/22 10:38:16 Stock Equity
Iterum Therapeutics plc (NASDAQ:ITRM) with the stream of -1.33% also noticed, India United States Antimony Corporation (AMEX:UAMY) encountered a rapid change of 1.58% in the last hour of Tuesdays trading The post Golden Stock: Iterum Therapeutics plc (NASDAQ:ITRM), United States Antimony Corporation (AMEX:UAMY) appeared first on Stocks Equity .
Traders should follow this: Iterum Therapeutics plc (NASDAQ:ITRM), KAR Auction Services, Inc. (NYSE:KAR) 2021/12/20 00:44:26 Stock Equity
Iterum Therapeutics plc (NASDAQ:ITRM) with the stream of 1.06% also noticed, India KAR Auction Services, Inc. (NYSE:KAR) encountered a rapid change of 2.33% in the last hour of Fridays trading The post Traders should follow this: Iterum Therapeutics plc (NASDAQ:ITRM), KAR Auction Services, Inc. (NYSE:KAR) appeared first on Stocks Equity .
Glowing Stocks Review: Iterum Therapeutics plc (NASDAQ:ITRM), Avino Silver & Gold Mines Ltd. (AMEX:ASM) 2021/12/16 00:05:30 Stock Equity
Iterum Therapeutics plc (NASDAQ:ITRM) with the stream of 7.63% also noticed, India Avino Silver & Gold Mines Ltd. (AMEX:ASM) encountered a rapid change of -1.94% in the last hour of The post Glowing Stocks Review: Iterum Therapeutics plc (NASDAQ:ITRM), Avino Silver & Gold Mines Ltd. (AMEX:ASM) appeared first on Stocks Equity .
Hot Mover to Watch: Iterum Therapeutics plc (NASDAQ:ITRM), Canadian Pacific Railway Limited (NYSE:CP) 2021/12/14 23:36:37 Stock Equity
Iterum Therapeutics plc (NASDAQ:ITRM) with the stream of -3.18% also noticed, India Canadian Pacific Railway Limited (NYSE:CP) encountered a rapid change of 2.88% in the last hour of Tuesdays trading The post Hot Mover to Watch: Iterum Therapeutics plc (NASDAQ:ITRM), Canadian Pacific Railway Limited (NYSE:CP) appeared first on Stocks Equity .